Visana Health raises $24M to scale virtual medical home for women
Expanding into weight loss, cardiometabolic care, and chronic condition management
Minneapolis-based Visana Health has raised $24 million in Series A funding to expand its nationwide women’s health platform into weight loss, cardiometabolic care, and chronic condition management, including diabetes, thyroid disorders, and cardiovascular disease.
The round was led by Noro-Moseley Partners, with participation from The Cigna Group Ventures, Intermountain Ventures, Flare Capital Partners, and Frist Cressey Ventures.
Alongside its clinical expansion, Visana plans to deepen its AI-enabled care model and accelerate adoption with health plans and self-funded employers.
A virtual medical ‘home’ for women
Visana describes itself as the first virtual medical home designed for women.The average Visana patient, according to the company, is managing multiple chronic conditions at once - needs that are often overlooked by traditional healthcare delivery models.
“The reality is that many women in the workforce are silently managing multiple chronic conditions – the average Visana patient has 3 to 4. By not addressing this, employers carry unnecessary costs,” said Joe Connolly, Co-founder and CEO of Visana Health.
“This financing is a recognition of the extraordinary progress we’ve made since our seed round – scaling nationwide to all 50 states, expanding our clinical scope, and proving that women’s healthcare can deliver both outstanding outcomes and actuarily-verified cost savings at scale.”
Reining in hidden costs
Women’s health ranks among the top five cost categories for employers, yet nearly one-fifth of those costs are driven by concerns that aren’t reflected in claims data. Conditions like endometriosis, menopause, and PCOS are often underdiagnosed and undertreated, contributing to silent costs for both patients and employers.
Visana points to actuarial analysis showing its platform reduces employer medical costs by 34%, cuts unnecessary procedures by 78%, and delivers more than $2,400 in annual savings per enrollee.
Scaling a nationwide model
Since its 2023 seed round, Visana has grown quickly. Today, it partners with national and regional health plans covering more than 35 million lives, and works with over 40 employers representing more than one million employees.
The company is on track to serve nearly 50,000 women by the end of 2025, with its clinical scope already expanded to include endocrinology.
“Visana has consistently demonstrated a commitment to women’s health, helping many of our employees feel heard for the first time. Their secret sauce is the individualized care and tailored solutions they help provide for every patient,” said Michele Arnette, Lead Benefits Analyst, Lumen.
“Their solutions provide employees with top-notch benefits that exceed our high standards. Their dedication to customer satisfaction and ability to deliver value-added services make them an ideal partner for our organization.”
Challenging a narrow scope
Employers and payers are under increasing pressure to demonstrate value from health benefits. Women’s health, often marginalized to fertility and maternity, has historically been a blind spot. Visana’s model, which spans conditions from menstruation to menopause, challenges that narrow scope.
“Visana has achieved the pinnacle of healthcare—a care model that delivers measurable improvements in patient outcomes while reducing costs,” said Spence McClelland, General Partner at Noro-Moseley Partners.
“As we look for emerging, disruptive healthcare companies to support, Visana clearly fits that mold. We’re thrilled to back a team that is setting a new standard for comprehensive women’s health.”
The role of AI
Visana also plans to channel its new capital into expanding AI capabilities, with early results showing improvements in clinical documentation efficiency and provider workflows. Streamlining administration is positioned as a core part of the company’s mission - not just improving outcomes for women, but reducing burnout for the clinicians who treat them.